The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice.
The use of transcutaneous photodynamic therapy (PDT) has been investigated in the prevention of adjuvant enhanced arthritis in MRL/lpr mice. Mice receiving adjuvant were treated with PDT at 10-day intervals starting on the day of adjuvant administration. PDT was carried out by intravenous injection of the photosensitizer, benzoporphyrin derivative-monoacid ring A, followed by its transcutaneous activation with light. Adjuvant-injected animals displayed a delayed onset and reduced incidence and severity of arthritis when compared to untreated animals. Most importantly, inflammatory structural damage to cartilage and bone tissues was prevented by PDT. PDT was found to have no adverse effects on animals as assessed by mitogen responses, hematopoiesis, and serum enzyme levels. As mitogen-activated MRL/lpr splenocytes were shown to be more susceptible to in vitro photodynamic treatment, it is postulated that the observed effects were the result of selective destruction of adjuvant-activated lymphocytes in the circulation and/or joints.
Chowdhary
R K
RK
Department of Microbiology, University of British Columbia, Vancouver, Canada.
Ratkay
L G
LG
Neyndorff
H C
HC
Richter
A
A
Obochi
M
M
Waterfield
J D
JD
Levy
J G
JG
D000279:Administration, Cutaneous; D000818:Animals; D001169:Arthritis, Experimental / Q000517:prevention & control*; D003208:Concanavalin A / Q000494:pharmacology; D005260:Female; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008817:Mice, Mutant Strains; D010778:Photochemotherapy; D011166:Porphyrins / Q000097:blood / Q000627:therapeutic use
D011166:Porphyrins; D003208:Concanavalin A